WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801

Neuropsychopharmacology

Volumn 23, Issue 5, 2000, Pages 547-559

  Wȩdzony, Krzysztof ^a   MaćKowiak, Marzena ^a   Zaja̧czkowski, Wojciech ^a   Fijal, Katarzyna ^a   Chocyk, Agnieszka ^a   Czyrak, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Delayed alternation; Locomotor activity; MK 801; Prepulse inhibition; Schizophrenia; Serotonin 5 HT1A receptors; Startle reflex; WAY 100135; Working memory

Indexed keywords

DIZOCILPINE; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; STARTLE REFLEX; WORKING MEMORY;

ANIMAL; DIZOCILPINE MALEATE; HALLUCINOGENS; HISTOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MEMORY, SHORT-TERM; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PIPERAZINES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN ANTAGONISTS; STARTLE REACTION;

EID: 0343278972     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00150-0     Document Type: Article

References (77)

1. Adams B., Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci. 18:1998;5545-5554.
2. Arborelius L., Chergui K., Murase S., Nomikos G.G., Hook B.B., Chouvet G., Hacksell U., Svensson T.H. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol. 347:1993;353-362.
3. Arnsten A.F. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 11:1997;151-162.
4. Assie M.B., Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels. (S)-WAY100135, but not WAY100635, has partial agonist properties Eur J Pharmacol. 304:1996;15-21.
5. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci. 18:1998;8394-8401.
6. Bakshi V.P., Geyer M.A. Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience. 92:1999;113-121.
7. Boast C., Bartolomeo A.C., Morris H., Moyer J.A. 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol Learn Mem. 71:1999;259-271.
8. Burnet P.W., Eastwood S.L., Harrison P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. 15:1996;442-455.
9. Cadenhead K.S., Geyer M.A., Butler R.W., Perry W., Sprock J., Braff D.L. Information processing deficits of schizophrenia patients. Relationship to clinical ratings, gender and medication status Schizophr Res. 28:1997;51-62.
10. Carli M., Bonalumi P., Samanin R. WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid. Brain Res. 774:1997;167-174.
11. Carli M., Luschi R., Samanin R. S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol. 283:1995;133-139.
12. Carli M., Silva S., Balducci C., Samanin R. WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. Neuropharmacology. 38:1999;1165-1173.
13. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry. 46:1999;1388-1395.
14. Carlsson M.L. Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways? J Neural Transm. 94:1993;1-10.
15. Dulawa S.C., Hen R., Scearce-Levie K., Geyer M.A. Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl). 132:1997;125-134.
16. Floresco S.B., Seamans J.K., Phillips A.G. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J Neurosci. 17:1997;1880-1890.
17. Geyer M.A. Behavioral studies of hallucinogenic drugs in animals. Implications for schizophrenia research Pharmacopsychiatry. 2(suppl 31):1998;73-79.
18. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto-and heteroreceptor-mediated control of release. Neuroscience. 84:1998;413-429.
19. Goldman-Rakic P.S. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A. 93:1996;13473-13480.
20. Hajos-Korcsok E., Sharp T. 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo. Evidence for a role of both 5-HT1A and dopamine D1 receptors Eur J Pharmacol. 314:1996;285-291.
21. Hajos-Korcsok E., Sharp T. Effect of 5-HT(1A) receptor ligands on Fos-like immunoreactivity in rat brain. Evidence for activation of noradrenergic transmission Synapse. 34:1999;145-153.
22. Hamamura T., Lee Y., Fujiwara Y., Kuroda S. Serotonin1A receptor agonists induce Fos protein expression in the locus coeruleus of the conscious rat. Brain Res. 759:1997;156-159.
23. Harder J.A., Maclean C.J., Alder J.T., Francis P.T., Ridley R.M. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology (Berl). 127:1996;245-254.
24. Harrison P.J. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 122:1999;593-624.
25. Healy D.J., Meador-Woodruff J.H. Ionotropic glutamate receptor modulation of 5-HT6 and 5-HT7 mRNA expression in rat brain. Neuropsychopharmacology. 21:1999;341-351.
26. Ichikawa J., Kuroki T., Kitchen M.T., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol. 287:1995;179-184.
27. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
28. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine. From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology. 20:1999;201-225.
29. Jentsch J.D., Wise A., Katz Z., Roth R.H. Alpha-noradrenergic receptor modulation of the phencyclidine-and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex. Synapse. 28:1998;21-26.
30. Kinney G.G., Wilkinson L.O., Saywell K.L., Tricklebank M.D. Rat strain differences in the ability to disrupt sensorimotor gating are limited to the dopaminergic system, specific to prepulse inhibition, and unrelated to changes in startle amplitude or nucleus accumbens dopamine receptor sensitivity. J Neurosci. 19:1999;5644-5653.
31. Kuroki T., Ichikawa J., Dai J., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743:1996;357-361.
32. Lejeune F., Millan M.J. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors. WAY 100, 635- reversible actions of the highly selective ligands, flesinoxan and S 15535 Synapse. 30:1998;172-180.
33. 1A receptor mRNA in the dentate gyrus of the long-term adrenalectomized rats and rapid reversal by dexamethasone. Mol Brain Res. 19:1993;328-332.
34. Lodge D., Johnson K.M. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol Sci. 11:1990;81-86.
35. Loscher W., Annies R., Honack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett. 128:1991;191-194.
36. Loscher W., Honack D. The behavioural effects of MK-801 in rats. Involvement of dopaminergic, serotonergic and noradrenergic systems Eur J Pharmacol. 215:1992;199-208.
37. Loscher W., Honack D. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur J Pharmacol. 242:1993;99-104.
38. Maj J., Rogoz Z., Skuza G. Locomotor hyperactivity induced by MK-801 in rats. Pol J Pharmacol Pharm. 43:1991;449-458.
39. Maj J., Rogoz Z., Skuza G., Wȩdzony K. The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J Neural Transm. 103:1996;131-146.
40. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 2:1989;299-308.
41. Meller E., Goldstein M., Bohmaker K. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis. Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists Mol Pharmacol. 37:1990;231-237.
42. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine. A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci. 17:1997;2921-2927.
43. Ohno M., Watanabe S. Blockade of 5-HT1A receptors compensates loss of hippocampal cholinergic neurotransmission involved in working memory of rats. Brain Res. 736:1996;180-188.
44. Ohno M., Yamamoto T., Watanabe S. Working memory deficits induced by intrahippocampal administration of 8-OH-DPAT, a 5-HT1A receptor agonist, in the rat. Eur J Pharmacol. 234:1993;29-34.
45. Paxinos G., Watson G. The Rat Brain in Stereotaxic Coordinates. 4th ed:1986;Academic Press, San Diego.
46. Pessia M., Jiang Z.G., North R.A., Johnson S.W. Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res. 654:1994;324-330.
47. Piercey M.F., Smith M.W., Lum-Ragan J.T. Excitation of noradrenergic cell firing by 5-hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther. 268:1994;1297-1303.
48. Przegalinski E., Filip M. Stimulation of serotonin (5-HT)1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol. 8:1997;699-706.
49. Rasmusson A.M., Goldstein L.E., Deutch A.Y., Bunney B.S., Roth R.H. 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse. 18:1994;218-224.
50. Rigdon G.C., Weatherspoon J.K. 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther. 263:1992;486-493.
51. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 338:1997;R3-R5.
52. Romanides A.J., Duffy P., Kalivas P.W. Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats. Neuroscience. 92:1999;97-106.
53. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release. Effects of competitive NMDA or 5-HT2A receptor blockade J Pharmacol Exp Ther. 277:1996;1541-1549.
54. Seamans J.K., Floresco S.B., Phillips A.G. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J Neurosci. 18:1998;1613-1621.
55. Seeburg P.H. The TiPS/TINS lecture. the molecular biology of mammalian glutamate receptor channels Trends Pharmacol Sci. 14:1993;297-303.
56. Sharp T., Bramwell S.R., Hjorth S., Grahame-Smith D.G. Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol. 98:1989;989-997.
57. Simpson M.D., Lubman D.I., Slater P., Deakin J.F. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry. 39:1996;919-928.
58. Sipes T.A., Geyer M.A. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology. 33:1994;441-448.
59. Sipes T.A., Geyer M.A. 8-OH-DPAT disruption of prepulse inhibition in rats. Reversal with (+)WAY 100,135 and localization of site of action Psychopharmacology (Berl). 117:1995;41-48.
60. Sprouse J.S., Reynolds L.S., Braselton J.P., Rollema H., Zorn S.H. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine. Inhibition of dorsal raphe cell firing and the role of 5- HT1A receptor activation Neuropsychopharmacology. 21:1999;622-631.
61. Stevens A.A., Goldman-Rakic P.S., Gore J.C., Fulbright R.K., Wexler B.E. Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging. Arch Gen Psychiatry. 55:1998;1097-1103.
62. Svensson A., Pileblad E., Carlsson M. A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm. 85:1991;117-129.
63. Swerdlow N.R., Mansbach R.S., Geyer M.A., Pulvirenti L., Koob G.F., Braff D.L. Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl). 100:1990;413-416.
64. Swerdlow N.R., Varty G.B., Geyer M.A. Discrepant findings of clozapine effects on prepulse inhibition of startle. Is it the route or the rat? Neuropsychopharmacology. 18:1998;50-56.
65. Varty G.B., Bakshi V.P., Geyer M.A. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology. 20:1999;311-321.
66. Varty G.B., Higgins G.A. Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol. 287:1995;201-205.
67. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats. modulation by dopamine J Neurosci. 16:1996;373-379.
68. Wachtel H., Turski L. Glutamate. a new target in schizophrenia? Trends Pharmacol Sci. 11:1990;219-220.
69. Wȩdzony K., Czyrak A. The distribution of the NMDA R1 subunit in the rat hippocampus - an immunocytohistochemical study. Brain Res. 768:1997;333-337.
70. Wȩdzony K., Czyrak A., Maćkowiak M., Fijal K. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra. Naunyn Schmiedebergs Arch Pharmacol. 353:1996;517-527. a.
71. Wȩdzony K., Golembiowska K., Zazula M. Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol. 350:1994;555-562.
72. Wȩdzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 622:1993;325-329.
73. Wȩdzony K., Maćkowiak M., Czyrak A., Fijal K., Michalska B. Single doses of MK-801, a non-competitive antagonist of NMDA receptors, increase the number of 5-HT1A serotonin receptors in the rat brain. Brain Res. 756:1997;84-91.
74. Wȩdzony K., Maćkowiak M., Fijal K., Golembiowska K. Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex. Eur J Pharmacol. 305:1996;73-78. b.
75. Whitton P.S., Biggs C.S., Pearce B.R., Fowler L.J. MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem. 58:1992;1573-1575.
76. Willetts J., Balster R.L., Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci. 11:1990;423-428.
77. Yan Q.S., Reith M.E., Jobe P.C., Dailey J.W. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res. 765:1997;149-158.